Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00834223
Other study ID # OPK-04-101
Secondary ID
Status Completed
Phase N/A
First received February 2, 2009
Last updated March 31, 2011
Start date January 2009
Est. completion date May 2010

Study information

Verified date March 2011
Source OPKO Health, Inc.
Contact n/a
Is FDA regulated No
Health authority Dominican Republic: Secretaría del Estado de Salud Pública y Asistencia Social (SESPAS)
Study type Interventional

Clinical Trial Summary

A prospective, multicenter, open-label, safety and preliminary efficacy study of the surgical implantation of OPKO's glaucoma drainage device (AquashuntTM) in patients with refractory chronic forms of open angle glaucoma (OAG). The primary objective of this study is to evaluate the surgical implantation, safety and preliminary efficacy of the AquashuntTM after implantation in patients with refractory chronic forms of OAG


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date May 2010
Est. primary completion date September 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

Patients of either sex will be eligible for the study if all of the following criteria are met:

1. Patients must be aged 18 years or more.

2. Patients must have a diagnosis of chronic forms of open angle glaucoma in the study eye, which is uncontrolled on maximum tolerated medical treatment with ocular hypotensive medications and has failed glaucoma surgery or is not considered a reasonable candidate for traditional surgery.

3. The patient's documented IOP must be considered by the treating physician to be too high for their glaucoma status.

4. Patients must have BCVA of between 20/400 and Light Perception, or no light perception with pain, in the study eye.

5. Patients must have a BCVA in the fellow eye, which is better than that of the study eye.

6. Patients must be mentally competent and willing to provide informed consent.

7. Patients must be willing to return for all study visits and assessments for at least 3 years after surgery.

Exclusion Criteria

Patients will not be eligible for the study if any of the following criteria are present:

1. Patients with a diagnosis of glaucoma other than open angle glaucoma including active uveitic, active neovascular or recent traumatic glaucoma.

2. Patients with clinically significant corneal disease including corneal dystrophy.

3. Patients with iridocorneal endothelial syndrome.

4. Any previous ocular surgery other than trabeculectomy, trabeculoplasty or cataract surgery and any surgery (including laser) within previous 3 months.

5. Patients with an Anterior Chamber configuration that puts the patient at high risk for the development of angle closure glaucoma.

6. Patients with any recent (within previous 30 days), or current, ocular/periocular inflammation or infection.

7. Patients with a history of extensive keloid formation.

8. Patients who will need ancillary procedures in the study eye at the time of implantation or during the initial one year study period.

9. Patients who have any known intolerance or hypersensitivity to topical anesthetics, mydriatics or components of the device.

10. Patients who are unable to interrupt their anti-coagulant, anti-platelet or NSAID (including aspirin) therapy for at least 3 weeks prior to surgery.

11. Patients who have within the previous 3 months, are currently, or intend to participate in a study with any investigational agent (drug or device).

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Aquashunt
A shunt which is implanted into the suprachoroidal space.

Locations

Country Name City State
Dominican Republic Centro Laser Santo Domingo

Sponsors (1)

Lead Sponsor Collaborator
OPKO Health, Inc.

Country where clinical trial is conducted

Dominican Republic, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary efficacy measure: The percentage change in IOP from baseline to 6 months and 12 months post-implantation. 6 and 12 months No
Secondary Secondary efficacy measure: The change in the number of glaucoma medications from baseline at 6 and 12 months post-implantation. 6 and 12 months No
Secondary Safety measures: The incidence of device and procedure-related complications. All adverse events reported, whether deemed related to the treatment or not. 3 years Yes
See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT02520674 - Glaucoma Screening With Smartphone Ophthalmology N/A
Completed NCT02246764 - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Phase 3
Completed NCT02653963 - Triamcinolone for Ahmed Glaucoma Valve N/A